Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Ovarian CancerOvarian Cancer Metastatic Recurrent
Interventions
DRUG

Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)

"\- Intervention Arm: Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor). Name: Propranolol (slow-Release) and Etodolac.~Propranolol Dosage Schedule:~5 days pre-surgery: 20mg twice daily (BID), Day of surgery: 80mg BID,~1-week Post-surgery: 40mg BID, week 2-11 post-surgery: 20mg BID.~Etodolac Dosage Schedule:~5 days pre-surgery until 3 weeks post-surgery: 400mg BID.~Administration Route: Oral."

DRUG

Placebo (Matching for Propranolol & Etodolac)

\- Placebo Arm: Placebo (Matching for Propranolol \& Etodolac). Inert placebo tablets matching propranolol and etodolac in appearance and dosing schedule. Administration Route: Oral.

Trial Locations (2)

5266202

RECRUITING

The Chaim Sheba Medical Center, Ramat Gan

6997801

RECRUITING

Tel Aviv Sourasky Medical Center (Ichilov Hospital), Tel Aviv

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

The Chaim Sheba Medical Center

OTHER

lead

Tel-Aviv Sourasky Medical Center

OTHER_GOV